Publications by authors named "Manos Perros"

Claim this Profile
S
Spiropyrimidinetriones: a Class of DNA Gyrase Inhibitors with Activity against Mycobacterium tuberculosis and without Cross-Resistance to Fluoroquinolones.
Gregory S Basarab, Sandeep Ghorpade, Liezl Gibhard, Rudolf Mueller, Mathew Njoroge, Manos Perros

Antimicrob Agents Chemother· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges and opportunities in the discovery, development, and commercialization of pathogen-targeted antibiotics.
David Altarac, Michael Gutch, John Mueller, Matthew Ronsheim, Ruben Tommasi, Manos Perros

Drug Discov Today· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Untargeted Metabolomics To Ascertain Antibiotic Modes of Action.
Isabel M Vincent, David E Ehmann, Scott D Mills, Manos Perros, Michael P Barrett

Antimicrob Agents Chemother· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum: Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases.
Gregory S Basarab, Gunther H Kern, John McNulty, John P Mueller, Kenneth Lawrence, Manos Perros

Sci Rep· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases.
Gregory S Basarab, Gunther H Kern, John McNulty, John P Mueller, Kenneth Lawrence, Manos Perros

Sci Rep· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infectious disease. A sustainable model for antibiotics.
Manos Perros

Science· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease-modifying therapeutic concepts for HIV in the era of highly active antiretroviral therapy.
Scott L Butler, Hernan Valdez, Michael Westby, Manos Perros, Carl H June

J Acquir Immune Defic Syndr· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.
Jonathan M Schapiro, Charles A B Boucher, Daniel R Kuritzkes, David A van de Vijver, Josep M Llibre, Manos Perros

Antivir Ther· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798).
Paul A Stupple, David V Batchelor, Martin Corless, Patrick K Dorr, David Ellis, Manos Perros

J Med Chem· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV capsid is a tractable target for small molecule therapeutic intervention.
Wade S Blair, Chris Pickford, Stephen L Irving, David G Brown, Marie Anderson, Manos Perros

PLoS Pathog· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
Romuald Corbau, Julie Mori, Chris Phillips, Lesley Fishburn, Alex Martin, Manos Perros

Antimicrob Agents Chemother· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41.
Edward J Murray, Daniel P Leaman, Nishant Pawa, Hannah Perkins, Chris Pickford, Manos Perros

J Virol· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation.
Wade S Blair, Joan Cao, Juin Fok-Seang, Paul Griffin, Jason Isaacson, Manos Perros

Antimicrob Agents Chemother· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrazole NNRTIs 1: design and initial optimisation of a novel template.
Charles E Mowbray, Catherine Burt, Romuald Corbau, Manos Perros, Isabelle Tran

Bioorg Med Chem Lett· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrazole NNRTIs 3: optimisation of physicochemical properties.
Charles E Mowbray, Romuald Corbau, Michael Hawes, Lyn H Jones, James E Mills, Manos Perros

Bioorg Med Chem Lett· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
Charles E Mowbray, Catherine Burt, Romuald Corbau, Simon Gayton, Michael Hawes, Manos Perros

Bioorg Med Chem Lett· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a small molecule inhibitor through interference with the gp120-CD4 interaction.
David H Williams, Fiona Adam, David R Fenwick, Juin Fok-Seang, Iain Gardner, Manos Perros

Bioorg Med Chem Lett· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and optimisation of potent gp120-CD4 inhibitors.
Thien-Duc Tran, Fiona M Adam, Frederick Calo, David R Fenwick, Juin Fok-Seang, Manos Perros

Bioorg Med Chem Lett· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CCR5 pharmacology methodologies and associated applications.
Roy Mansfield, Sarah Able, Paul Griffin, Becky Irvine, Ian James, Manos Perros

Methods Enzymol· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overcoming hERG affinity in the discovery of maraviroc; a CCR5 antagonist for the treatment of HIV.
David A Price, Duncan Armour, Marcel de Groot, Derek Leishman, Carolyn Napier, Manos Perros

Curr Top Med Chem· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays.
Lyn H Jones, Gill Allan, Oscar Barba, Catherine Burt, Romuald Corbau, Manos Perros

J Med Chem· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of 5-aryloxyimidazole non-nucleoside reverse transcriptase inhibitors.
Lyn H Jones, Gill Allan, Romuald Corbau, Duncan Hay, Donald S Middleton, Manos Perros

ChemMedChem· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CCR5 inhibitors in HIV-1 therapy.
Patrick Dorr, Manos Perros

Expert Opin Drug Discov· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An inhibitor of the epidermal growth factor receptor function does not affect the ability of human papillomavirus 11 to form warts in the xenografted immunodeficient mouse model.
Tanya Parkinson, Mary K Howett, Patricia A Welsh, Susan D Patrick, Elizabeth B Neely, Manos Perros

Antiviral Res· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
Mike Westby, Caroline Smith-Burchnell, Julie Mori, Marilyn Lewis, Michael Mosley, Manos Perros

J Virol· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis